This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignees: Purdue Research Foundation, University of Florida Research Foundation Inc.. Active years: 2022-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Palm, FL (US) (2022)
- Palm City, FL (US) (2023)
Company Filing History:
3 out of 2,781 
3 out of 3,050 
Years Active: 2022-2026
Title: Alexander Adibekian: Innovator in Sesquiterpenoid Compounds
Introduction
Alexander Adibekian is a notable inventor based in Palm, FL (US). He has made significant contributions to the field of cancer treatment through his innovative work on sesquiterpenoid compounds. With a total of 3 patents, his research focuses on developing novel compounds that can potentially enhance the effectiveness of cancer therapies.
Latest Patents
Adibekian's latest patents include groundbreaking work on sesquiterpenoid analogs. The present disclosure relates to novel sesquiterpenoid compounds that act as SHP2 and/or POLE3 inhibitors for potential cancer treatment. These compounds are designed to be used as chemosensitization agents alongside DNA-damaging drugs, thereby improving therapeutic outcomes for cancer patients.
Career Highlights
Throughout his career, Alexander Adibekian has been associated with reputable institutions such as the Purdue Research Foundation and the University of Florida Research Foundation, Incorporated. His work in these organizations has allowed him to advance his research and contribute to the scientific community.
Collaborations
Adibekian has collaborated with esteemed colleagues, including Mingji Dai and Dexter Cameron Davis. These partnerships have further enriched his research endeavors and have played a crucial role in the development of his innovative compounds.
Conclusion
Alexander Adibekian stands out as a prominent inventor in the field of cancer research, particularly through his work on sesquiterpenoid compounds. His contributions have the potential to significantly impact cancer treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile